1. Low-dose col- 1.2 mg at first sign of flare, followed by 0.6 mg one hour
chine later for a total dose of 1.8 mg.
2. High-dose col- 1.2 mg followed by 0.6 mg every 4-6 hours totaling 4.8 mg.
chine
3. Gout BUN, creatinine, and creatinine clearance should be mon-
itored in the treatment of this disease
4. Colchine This medication can cause severe diarrhea, nausea, vom-
iting, abdominal pain
5. Febuxostat When prescribing this medication, patients should be
(Uloric) taught that gout may worsen with therapy before it im-
proves
6. Corticosteroids These medications can cause the following adverse ef-
fects if taken for six months or more: Osteoporosis and
poor diabetic control. Patients should report black, tarry
stools or abdominal pain.
7. Corticosteroids These medications should be tapered to avoid recurrent
activity of the underlying disease and possible cortisol de-
ficiency resulting from the hypothalamic-pituitary-adrenal
axis suppression during the period of steroid therapy.
8. Black Box Warn- Increased risk of serious cardiovascular thrombotic
ing on NSAIDS events, such as myocardial infarction and stroke. These
medications can also cause serious GI events such
as bleeding, ulceration or perforation of stomach or in-
testines, which can be fatal.
9. Pain manage- When treating this common issue, it is recommended to
ment begin with NSAIDS and work up from there as needed
10. Ibuprofen This medication works by inhibiting the COX enzymes;
however, the exact mechanism of action for this particular
medication is unknown.
11. Acetaminophen
1/7
, Maryville University Nursing 615 Exam 3 Review with Verified Solutions
A serious adverse effect related to this medication is re-
ferred to as " -------------poisoning"
12. Symptoms of hy- Decreased LOC, hunger, diaphoresis, weakness, dizzi-
poglycemia ness and tachycardia
13. Symptoms of hy- Polyuria, polydipsia and polyphagia (weight loss)
perglycemia
14. Symptoms of Kussmaul's respiration, ketone odor of the breath (fruity
DKA breath), vomiting, dehydration, abdominal pain, and neu-
rologic symptoms such as lethargy; can progress to coma
in later stages if left untreated.
15. Metformin This medication decreases hepatic glucose output inhibit-
ing gluconeogenesis. It also increases insulin mediated
glucose utilization in peripheral tissues. This medication
decreases intestinal absorption of glucose. This medica-
tion may also be used in diabetics to decrease cholesterol
and triglyceride levels.
16. Metformin When patients are prescribed this medication, the primary
care provider should assess serum creatinine, renal func-
tion, and creatinine clearance initially and annually.
17. Gliptins (DPP4 These medications increase the incretin levels, which in-
inhibitors) hibit glucagon release; this subsequently increases in-
sulin secretion, decreases gastric emptying and decreas-
es blood glucose levels.
18. GLP-1 agonists These medications bind directly to the GLP-1 receptor,
which then slows gastric emptying and increases insulin
secretion by pancreatic beta cells.
19. Exenatide (Byet- This medication should be administered 60 minutes be-
ta) fore breakfast and dinner.
20. PTU Adverse effects of this medication include fatal granulocty-
openia (presents as fever and slow throat), vasculitis, tem-
2/7